Skip to main
IFRX

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx is a biopharmaceutical company with a positive outlook, driven by its promising product candidates, vilobelimab and izicopan, which target the C5a/C5aR pathway to treat autoimmune and inflammatory diseases. The company recently announced positive 1Q26 earnings and is expected to have enough cash to fund its operations through 2029. In addition to AAV, the company plans to evaluate izicopan's efficacy in various inflammatory renal diseases, providing multiple potential opportunities for success. However, there are risks to consider, such as clinical trial failures and difficulty in demonstrating superiority over current standard of care treatments. Overall, InflaRx's strong clinical focus, potential partnerships, and successful development of its C5a/C5aR inhibitors make it an attractive investment opportunity.

Bears say

InflaRx is a clinical-stage biotechnology company with a focus on developing anti-inflammatory therapeutics targeting the C5a/C5aR complement pathway. The company has a limited commercialization for its COVID treatment and is currently in a Phase 2a basket study for its C5aR inhibitor in CSU and HS. However, their increased pursuit of development in ANCA vasculitis may pose potential financial risks and uncertainties, making us maintain our negative outlook on their stock.

InflaRx (IFRX) has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 5 analysts, InflaRx (IFRX) has a Buy consensus rating as of Jun 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.